Cramer on how Eli Lilly could be impacted by mixed Alzheimer's drug study results

Eli Lilly said its experimental treatment for Alzheimer’s modestly slowed decline in patients over an 18-month period in a mid-stage study. Lilly has already begun a second study of the treatment. Lilly fell 5.3% in the premarket Monday. CNBC's Jim Cramer reacts to the news.